
Mabion S.A.
WSE:MAB.WA
19.28 (PLN) • At close December 14, 2023
Overzicht | Financiële gegevens
Bedrijfsnaam | Mabion S.A. |
Symbool | MAB.WA |
Munteenheid | PLN |
Prijs | 19.28 |
Beurswaarde | 311,609,125 |
Dividendpercentage | 0% |
52-weken bereik | 15.8 - 24.9 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Krzysztof Kaczmarczyk |
Website | https://www.mabion.eu |
An error occurred while fetching data.
Over Mabion S.A.
Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (PLN)
Cijfers zijn in miljoenen (PLN)